

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Betrixaban for preventing venous thromboembolism in people hospitalised for an acute medical condition ID913

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company(ies)</u></p> <ul style="list-style-type: none"> • Portola Pharmaceuticals (betrixaban) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • AntiCoagulation Europe-UK • British Lung Foundation • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • Thrombosis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Renal Technologists • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Heart Rhythm Society • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Thoracic Society • Clinical Leaders of Thrombosis • British Society for Heart Failure • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Vascular Anaesthesia Society of Great Britain and Ireland • Vascular Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British Cardiovascular Industry Association • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium <p><u>Possible Comparator Companies</u></p> <ul style="list-style-type: none"> • Baxter Healthcare (heparin sodium) • Aspen Pharmacare (fondaparinux sodium) • LEO Pharma (heparin sodium, tinzaparin sodium) • Pfizer (dalteparin sodium) • Sanofi (enoxaparin sodium) • Sigma Pharmaceuticals (enoxaparin sodium) • Wockhardt UK (heparin calcium, heparin sodium) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Circulation Foundation

Appendix C

Consultees	Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"> • Department of Health • NHS Chorley and South Ribble CCG • NHS England • NHS South Sefton CCG • Welsh Government 	<ul style="list-style-type: none"> • Cochrane Peripheral Vascular Disease Group • Cochrane Stroke Group • MRC Clinical Trials Unit • National Centre for Cardiovascular Preventions and Outcomes • National Institute for Health Research • Thrombosis Research Institute • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.